Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond

Cantor, David J.; Aggarwal, Charu

doi:10.1158/1078-0432.CCR-23-1658

Article navigation

CCR Translations| September 15 2023

Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond

David J. Cantor

0000-0003-4084-3312

;

David J. Cantor

1Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Charu Aggarwal

0000-0002-3181-9460

Charu Aggarwal *

1Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

2Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

3Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania.

*Corresponding Author: Charu Aggarwal, Leslye M. Heisler Associate Professor of Lung Cancer Excellence, Department of Medicine, Hematology-Oncology Division, University of Pennsylvania, 10-137, South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104. Phone: 215-662-6318; Fax: 215-349-5326; E-mail: [email protected]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Author & Article Information

*Corresponding Author: Charu Aggarwal, Leslye M. Heisler Associate Professor of Lung Cancer Excellence, Department of Medicine, Hematology-Oncology Division, University of Pennsylvania, 10-137, South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104. Phone: 215-662-6318; Fax: 215-349-5326; E-mail: [email protected]

Clin Cancer Res 2023;29:3563–5

Received: June 20 2023

Revision Received: July 07 2023

Accepted: July 14 2023

Online ISSN: 1557-3265

Print ISSN: 1078-0432

2023

American Association for Cancer Research

Clin Cancer Res (2023) 29 (18): 3563–3565.

https://doi.org/10.1158/1078-0432.CCR-23-1658

Summary

KRAS-mutated non–small cell lung cancer (NSCLC) is the most common genetically altered subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated combinations of MEK inhibitors with chemotherapy without success. Here we discuss these studies and novel approaches to targeting KRAS-mutated NSCLC.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond

Summary

Citing articles via

Email alerts

AACR Journals

Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond Available to Purchase

Summary

Sign in

Client Account

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond